Der Onkologe

, Volume 11, Issue 9, pp 948–958

Behandlung von Progressen und Rezidiven des Hodgkin-Lymphoms

Leitthema
  • 35 Downloads

Zusammenfassung

Patienten mit Progress, Früh- oder Spätrezidiv eines Hodgkin-Lymphoms sollten einer HDCT und autologen Stammzelltransplantation zugeführt werden. Die allogene Stammzelltransplantation ist weiterhin ein experimentelles Verfahren beim Hodgkin-Lymphom.

Durch die großen Fortschritte in der Primärtherapie werden in Zukunft deutlich weniger Patienten einen Progress oder ein Rezidiv erleiden. Um die Salvagetherapie weiter zu verbessern, sollten primär progrediente und rezidivierte Hodgkin-Lymphome deshalb unbedingt in klinischen Studien behandelt werden. Aktuelle Studienprotokolle können über die DHSG (Tel. 0221–478–6032) bezogen werden.

Schlüsselwörter

Rezidiviertes Hodgkin-Lymphom Stammzelltransplantation Salvagetherapie Hochdosistherapie 

Treating progressive and relapsed Hodgkin’s lymphoma

Abstract

Patients with primary progressive or relapsed Hodgkin’s lymphoma after first-line polychemotherapy should be treated with HDCT and autologous stem cell transplantation. Allogeneic transplantation should be considered as an experimental strategy. Based on the excellent results with primary treatment only a few patients will suffer disease progression or relapse. To further improve salvage therapy, patients should therefore be treated within clinical trials. For further information please contact the German Hodgkin Study office (Phone: +49(0)221–478–6032).

Keywords

Relapsed Hodgkin’s lymphoma Cell transplantation Salvage therapy HDCT 

Literatur

  1. 1.
    Rueffer U, Josting A, Franklin J et al. (2001) Non-Hodgkin‚s lymphoma after primary Hodgkin‘s disease in the German Hodgkin‚s Lymphoma Study Group (GHSG) — Incidence, treatment and prognosis. J CliN Oncol 19:2026–2032Google Scholar
  2. 2.
    Josting A, Behringer K, Engert A et al. (2004) Moderne Pharmakotherapie des Morbus Hodgkin. Internist 45:93–101Google Scholar
  3. 3.
    Horwich A, Specht L, Ashley S et al. (1997) Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 33:848–856Google Scholar
  4. 4.
    Roach MD, Brophy N, Cox R et al. (1990) Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol 8:623–629Google Scholar
  5. 5.
    Sieber M, Franklin J, Tesch H et al. (2002) Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin‚s disease: Results of the German Hodgkin‚s Lymphoma Study Group (GHSG). Blood 100:341Google Scholar
  6. 6.
    Carde P, Noordijk EM, Hagenbeck A et al. (1998) EBVP chemotherapy plus irradiation provides Event-Free Survival (EFS) superior to subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin‚s disease, but inferior to MOPP-ABV plus irradiation in unfavorable cases: The EORTC-GPMC H7 randomized trials. Leuk Lymph 29 [Suppl 1]:6Google Scholar
  7. 7.
    Mauch P, Henry-Amar M (1992) International Database on Hodgkin’s Disease: a cooperative effort to determine treatment outcome. Ann Oncol 3 [Suppl 4]:59Google Scholar
  8. 8.
    Specht L, Horwich A, Ashley S et al. (1994) Salvage of relapse of patients with Hodgkin’s disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin’s disease. Int J Radiat Oncol Biol Phys 30:805Google Scholar
  9. 9.
    Cannellos G, Young RC, De Vita VD et al. (1972) Combination chemotherapy for advanced Hodgkin‚s disease in relapse following extensive radiotherapy. Clin Pharm Ther 13:750–758Google Scholar
  10. 10.
    Santoro A, Viviani S, Villarreal C et al. (1986) Salvage chemotherapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343–348Google Scholar
  11. 11.
    Rüffer JU, Glossmann JP, Sieber M et al. (2005) BEACOPP and COPP/ABVD as salvage treatment for relpase after primary extended field radiation therapy of early stage Hodgkin’s disease — Results of the German Hodgkin Lymphoma study group. Leuk Lymph (in press)Google Scholar
  12. 12.
    Fisher R, De VV, Hubbard S et al. (1979) Prolonged disease-free survival in Hodgkin’s disease with MOPP reinduction after first relapse. Ann Intern Med 90:761–766Google Scholar
  13. 13.
    Longo D, Duffey P, Young R et al. (1992) Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 10:210Google Scholar
  14. 14.
    Josting A, Franklin J, May M et al. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin lymphoma registered in the database of the German Hodgkin Lymphoma Study Group (GHSG). J Clin Oncol 20:221–230Google Scholar
  15. 15.
    Wirth A, Corry J, Laidlaw C et al. (1997) Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 39:599Google Scholar
  16. 16.
    Brada M, Eeles R, Ashley S et al. (1992) Salvage radiotherapy in recurrent Hodgkin’s disease. Ann Oncol 3:131Google Scholar
  17. 17.
    Leigh B, Fox K, Mack C et al. (1993) Radiation therapy salvage of Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 27:855Google Scholar
  18. 18.
    Pezner R, Nademanee A, Forman S et al. (1995) High-dose therapy and autologous bone marrow transplantation for Hodgkin’s disease patients with relapses potentially treatable by radical radiation therapy. Int J Radiat Oncol Biol Phys 33:189–194Google Scholar
  19. 19.
    Josting A, Nogova L, Franklin J et al. (2005) Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma — A retrospective analysis from the German Hodgkin Lymphoma Study Group. J Clin Oncol 23:1522–1529Google Scholar
  20. 20.
    Pfreundschuh M, Rueffer U, Lathan B et al. (1994) Dexa-BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 12:580–589Google Scholar
  21. 21.
    Hagemeister F, Tannir N, McLaughlin P et al. (1987) MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin’s disease. J Clin Oncol 5:556–561Google Scholar
  22. 22.
    Rodriguet MG, Schoppe WD, Fuchs R et al. (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin‚s disease refractory to cyclophosphamide, vincristine, procarbacine, and prednisone (COPP) and doxorubicine, bleomycin, vinblastine, and darcarbazine (ABVD): A multi-center trial of the German Hodgkin‚s study group. Cancer Treatment Rep 71:1203–1229Google Scholar
  23. 23.
    Ferme C, Bastion Y, Lepage E et al. (1995) The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann Oncol 6:543–570Google Scholar
  24. 24.
    Rodriguez J, Rodriguez MA, Fayad L et al. (1999) ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin’s disease. Blood 93:3632–3636Google Scholar
  25. 25.
    Aparicio J, Segura A, Garcera S et al. (1999) ESHAP is an active regimen for relapsing Hodgkin’s disease. Ann Oncol 10:593–595Google Scholar
  26. 26.
    Josting A, Rudolph C, Reiser M et al. (2002) Time intensified DHAP — An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin’s disease. Ann Oncol 13:1628–1635Google Scholar
  27. 27.
    Bierman P, Bagin R, Jagannath et al. (1993) High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin’s disease: long-term follow-up in 128 patients. Ann Oncol 4:767–771Google Scholar
  28. 28.
    Reece D, Barnett M, Shepherd J et al. (1995) High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16–213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin’s disease who fail to enter a complete remission after combination chemotherapy. Blood 86:451–458Google Scholar
  29. 29.
    Josting A, Katay I, Rueffer U et al. (1998) Favorable outcome of patients with relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dexa-BEAM). Ann Oncol 9:289–295Google Scholar
  30. 30.
    Linch D, Winfield D, Goldstone A et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341:1051–1054Google Scholar
  31. 31.
    Schmitz N, Pfistner B, Sextro M et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359:2065–2071Google Scholar
  32. 32.
    Sweetenham JW, Carella AM, Taghipour GB et al. (1999) High-dose therapy and autologous stem cell transplantation for adult patients with Hodgkin‚s disease who fail to enter remission after induction chemotherapy: Results in 175 patients reported to the EBMT. J Clin Oncol 17:3101Google Scholar
  33. 33.
    Lazarus H, Rowlings P, Zhang M et al. (1999) Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17:534Google Scholar
  34. 34.
    Horning SJ, Chao NJ, Negrin RS et al. (1997) High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent and refractory Hodgkin‚s disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801–813Google Scholar
  35. 35.
    Gianni AM, Bregni M, Siena S et al. (1993) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin‚s disease: A 6-year update. Ann Oncol 4:889–891Google Scholar
  36. 36.
    Josting A, Rueffer U, Franklin J et al. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin Lymphoma—a report from the German Hodgkin Lymphoma Study Group (GHSG). Blood 96:1280–1286Google Scholar
  37. 37.
    Josting A, Reiser M, Rueffer U et al. (2000) Treatment of Primary Progressive Hodgkin’s and Aggressive Non-Hodgkin’s Lymphoma: Is There a Chance for Cure? J Clin Oncol 18:332–339Google Scholar
  38. 38.
    Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395Google Scholar
  39. 39.
    Yuen A, Rosenberg S, Hoppe R et al. (1997) Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 89:814–820Google Scholar
  40. 40.
    Milpied N, Fielding A, Pearce R et al. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin’s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291–1296Google Scholar
  41. 41.
    Anderson J, Litzow M, Appelbaum F et al. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 11:2342Google Scholar
  42. 42.
    Gajewski J, Phillips G, Sobocinski K et al. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 14:572–579Google Scholar
  43. 43.
    Gianni AM, Siena S, Bregni M et al. (1993) High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin‚s disease- A 6-year update. Ann Oncol 4:889–891Google Scholar
  44. 44.
    Gianni AM, Bregni M, Siena S et al. (1994) 5-year update of the Milan Cancer Institute randomized trial of high-dose sequential (HDS) vs MACOP-B therapy for diffuse large-cell lymphomas. Proc ASCO 13:373 (1263)Google Scholar
  45. 45.
    Shea T, Mason JR, Storniolo AM et al. (1992) Sequential cycles of high-dose carboplatin administered with recombinat human granulocyte-makrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. JCO 10:464–473Google Scholar
  46. 46.
    Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Canc Treat Rep 70:163–169Google Scholar
  47. 47.
    Josting A, Rudolph C, Mapara M et al. (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma – Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116–123Google Scholar
  48. 48.
    Borchmann P, Schnell R, Schulz H et al. (2004) Monoclonal antibody-based immunotherapy of Hodgkin’s lymphoma. Curr Opin Investig Drugs 12:1262–1267Google Scholar
  49. 49.
    Anderson JE, Litzow MR, Appelbaum R et al. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: The 21-year Seattle Experience. J Clin Oncol 11:2342–2350Google Scholar
  50. 50.
    Gajewski JL, Philips GL, Sobocinski K et al. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin’s disease. J Clin Oncol 14:572–578Google Scholar
  51. 51.
    Milpied N, Fielding AK, Pearce RM et al. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for Patients with relapsed Hodgkin’s disease. J Clin Oncol 14:1291–1296Google Scholar
  52. 52.
    Jones RJ, Ambinder RF, Piantadosi X et al. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653Google Scholar
  53. 53.
    Akpek G, Ambinder RF, Piantadosi S et al. (2001) Long-term results of blood and marrow transplantation for Hodgkin’s lymphoma. J Clin Oncol 19:4314–4321Google Scholar
  54. 54.
    Robinson SP, Goldstone AH, Mackinnon S et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310–4316Google Scholar
  55. 55.
    Anderlini P, Giralt S, Andersson B et al. (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimes as adoptive immunotherapy in advanced Hodgkin’s disease. BMT 26:615–620Google Scholar
  56. 56.
    Carella AM, Cavaliere M, Lerma E et al. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodkin’s disease and Non-Hodgkin’s lymphoma. J Clin Oncol 18:3918–3924Google Scholar
  57. 57.
    Chakraverty R, Peggs K, Chopra R et al. (2002) Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99:1071–1078Google Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Klinik I für Innere Medizin, Deutsche Hodgkin-Lymphom Studiengruppe (DHSG), Universität zu Köln
  2. 2.Abt. HämatologieAllgemeines Krankenhaus St. Georg, Köln
  3. 3.Klinik I für Innere Medizin, Universität zu KölnKöln

Personalised recommendations